Certara Announces Expansion of Clinical Technology Collaboration with Merck
Certara (Nasdaq: CERT) has expanded its technology collaboration with Merck to enhance clinical data management capabilities. The expanded partnership includes implementing Certara's Pinnacle 21 software platform for metadata repository and data standards workflow management, building upon their existing regulatory submissions collaboration.
The expansion addresses the growing complexity in clinical trial data management, where Phase III trials now average 3.6 million datapoints, representing a threefold increase over the past decade. The Pinnacle 21 platform aims to streamline data standardization for modern digital trials at scale.
Certara (Nasdaq: CERT) ha ampliato la sua collaborazione tecnologica con Merck per migliorare le capacit脿 di gestione dei dati clinici. La partnership estesa prevede l'implementazione della piattaforma software Pinnacle 21 di Certara per la gestione del repository di metadata e dei flussi di lavoro degli standard dati, rafforzando la loro collaborazione gi脿 esistente sulle sottomissioni regolatorie.
Questo ampliamento risponde alla crescente complessit脿 nella gestione dei dati degli studi clinici, dove gli studi di Fase III ora contano in media 3,6 milioni di punti dati, triplicando rispetto a un decennio fa. La piattaforma Pinnacle 21 mira a semplificare la standardizzazione dei dati per studi digitali moderni su larga scala.
Certara (Nasdaq: CERT) ha ampliado su colaboraci贸n tecnol贸gica con Merck para mejorar las capacidades de gesti贸n de datos cl铆nicos. La asociaci贸n ampliada incluye la implementaci贸n de la plataforma de software Pinnacle 21 de Certara para la gesti贸n del repositorio de metadatos y los flujos de trabajo de est谩ndares de datos, bas谩ndose en su colaboraci贸n existente en presentaciones regulatorias.
Esta expansi贸n responde a la creciente complejidad en la gesti贸n de datos de ensayos cl铆nicos, donde los ensayos de Fase III ahora promedian 3.6 millones de puntos de datos, lo que representa un aumento de tres veces en la 煤ltima d茅cada. La plataforma Pinnacle 21 busca optimizar la estandarizaci贸n de datos para ensayos digitales modernos a gran escala.
Certara (雮橃姢雼�: CERT)電� 鞛勳儊 雿办澊韯� 甏�毽� 鞐焿 臧曧檾毳� 鞙勴暣 Merck鞕�鞚� 旮办垹 順戨牓鞚� 頇曤寑頄堨姷雼堧嫟. 鞚措矆 頇曥灔霅� 韺岉姼雱堨嫮鞐愲姅 旮办〈鞚� 攴滌牅 鞝滌稖 順戨牓鞐� 鞚挫柎 Certara鞚� Pinnacle 21 靻岉攧韸胳洦鞏� 頂岆灚韽�鞚� 氅旐儉雿办澊韯� 鞝�鞛レ唽 氚� 雿办澊韯� 響滌 鞗岉伂頂岆鞖� 甏�毽棎 霃勳瀰頃橂姅 雮挫毄鞚� 韽暔霅╇媹雼�.
鞚措矆 頇曥灔鞚� 鞛勳儊鞁滍棙 雿办澊韯� 甏�毽潣 氤奠灐靹膘澊 歃濌皜頃橂姅 靸來櫓鞐� 雽�鞚戫暅 瓴冹溂搿�, 3靸� 鞛勳儊鞁滍棙鞚� 順勳灛 韽夑窢 360毵� 臧滌潣 雿办澊韯� 韽澑韸�毳� 韽暔頃橂┌ 歆�雮� 10雲勱皠 靹� 氚� 歃濌皜頄堨姷雼堧嫟. Pinnacle 21 頂岆灚韽检潃 雽�攴滊 順勲寑 霐旍韯� 鞛勳儊鞁滍棙鞚� 雿办澊韯� 響滌頇旊ゼ 臧勳唽頇旐晿電� 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
Certara (Nasdaq : CERT) a 茅tendu sa collaboration technologique avec Merck afin d'am茅liorer ses capacit茅s de gestion des donn茅es cliniques. Ce partenariat 茅largi inclut la mise en 艙uvre de la plateforme logicielle Pinnacle 21 de Certara pour la gestion du r茅f茅rentiel de m茅tadonn茅es et des flux de travail des normes de donn茅es, s'appuyant sur leur collaboration existante pour les soumissions r茅glementaires.
Cette extension r茅pond 脿 la complexit茅 croissante de la gestion des donn茅es des essais cliniques, o霉 les essais de phase III comptent d茅sormais en moyenne 3,6 millions de points de donn茅es, soit une multiplication par trois au cours de la derni猫re d茅cennie. La plateforme Pinnacle 21 vise 脿 simplifier la standardisation des donn茅es pour les essais num茅riques modernes 脿 grande 茅chelle.
Certara (Nasdaq: CERT) hat seine technologische Zusammenarbeit mit Merck ausgeweitet, um die F盲higkeiten im klinischen Datenmanagement zu verbessern. Die erweiterte Partnerschaft umfasst die Implementierung von Certaras Pinnacle 21 Softwareplattform f眉r Metadaten-Repositorium und Datenstandard-Workflow-Management und baut auf der bereits bestehenden Zusammenarbeit bei regulatorischen Einreichungen auf.
Die Erweiterung reagiert auf die zunehmende Komplexit盲t im Management klinischer Studiendaten, bei denen Phase-III-Studien jetzt durchschnittlich 3,6 Millionen Datenpunkte umfassen, was eine Verdreifachung gegen眉ber dem letzten Jahrzehnt darstellt. Die Pinnacle 21 Plattform soll die Datenstandardisierung f眉r moderne digitale Studien in gro脽em Ma脽stab vereinfachen.
- Expansion of existing partnership with major pharmaceutical company Merck
- Enhanced capability to handle complex clinical trial data management
- Strategic positioning in addressing growing clinical trial data challenges
- None.
Expands use of the Certara Pinnacle 21庐 (P21) enterprise software platform to optimize clinical data flows for speed and quality
RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck鈥檚 use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This agreement builds upon Merck鈥檚 existing technology collaboration with Certara to aid in regulatory submissions.
Reducing the time from data collection to validated, analysis-ready datasets has become more complex across drug development. Phase III clinical trials now average 3.6 million datapoints, a threefold increase over the last decade.1 The is designed to solve the data standardization challenges of modern digital trials at scale.
鈥淲e are pleased to strengthen our ongoing collaboration with Merck to assist with data standards management and to expand the value of the Pinnacle 21 platform,鈥� said William F. Feehery, Chief Executive Officer. 鈥淢erck is a premier research-intensive company, and our teams are well-aligned in the goal of delivering high-quality research data faster to help save and improve lives around the world.鈥�
To learn more about Pinnacle 21 Enterprise clinical data management and automation suite, please visit
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
听听
Media Contact:
Alyssa Horowitz
1 Tufts Center for the Study of Drug Development (CSDD) Impact Report November/December 2021
FAQ
What is the new collaboration between Certara and Merck in 2025?
How has clinical trial data complexity changed according to Certara's 2025 announcement?
What is the purpose of Certara's Pinnacle 21 platform?
Who is the CEO of Certara (CERT) in 2025?
How will the expanded Certara-Merck collaboration benefit clinical trials?
